Adenomyosis Treatment Market Analysis
ID: MRFR/Pharma/2331-HCR
76 Pages
October 2025
Adenomyosis Treatment Market Research Report Information By Type (Focal, Adenomyoma, Diffuse, and Others), By Diagnosis (Endometrial Biopsy, Ultrasound {Transabdominal, and Transvaginal/Endovaginal}, Magnetic Resonance Imaging (MRI), and Others), By Treatment (Anti-Inflammatory Drugs {Ibuprofen, Motrin IB, Advil, and Others}, Hormone Medications {Gonadotropin-Releasing Hormone (GnRH) Agonists, ...
Market Summary
The global adenomyosis treatment market is projected to grow from 0.34 USD billion in 2024 to 0.66 USD billion by 2035, reflecting a robust growth trajectory.
Key Market Trends & Highlights
Adenomyosis Treatment Key Trends and Highlights
- The market is expected to experience a compound annual growth rate (CAGR) of 6.19 percent from 2025 to 2035.
- By 2035, the market valuation is anticipated to reach 0.66 USD billion, indicating a substantial increase from the base year.
- in 2024, the market is valued at 0.34 USD billion, highlighting its current size and potential for growth.
- Growing adoption of advanced treatment options due to increasing awareness of adenomyosis is a major market driver.
Market Size & Forecast
| 2024 Market Size | 0.34 (USD Billion) |
| 2035 Market Size | 0.66 (USD Billion) |
| CAGR (2025-2035) | 6.20% |
| Largest Regional Market Share in 2024 | latin_america) |
Major Players
Mayne Pharma Group Limited, Accord Healthcare, Tolmar Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, TerSera Therapeutics LLC, Ferring B.V., Lannett, Par Pharmaceutical, Hikma Pharmaceuticals PLC, Context Therapeutics Inc., Viatris Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., AstraZeneca, Pfizer Inc., Zydus Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd., AbbVie Inc., Abbott, GlaxoSmithKline plc.
Market Trends
The high prevalence of adenomyosis disorders is driving the market growth
Market CAGR for adenomyosis treatment is driven by the increasing women population worldwide; the target population for female reproductive disorders has also increased. Adenomyosis, a gynecologic condition characterized by the existence of endometrial glands in the myometrium, can significantly reduce an individual's lifestyle. Adenomyosis occurs in 8.8% to 61.5% of women undergoing hysterectomy, and rates vary widely by differences in diagnostic criteria and variations between and within pathologists. The prevalence is estimated to range from 20% to 34%, based on patients referred for pelvic imaging rather than the general population of women. Gynecologic disorders affect the female reproductive system.
The most common symptoms of gynecologic disorders such as pelvic pain, abnormal vaginal bleeding, endometriosis, adenomyosis, and breast pain and lumps. The importance and severity of these signs often rely on age, as these symptoms may be connected to hormonal changes that happen with aging.
Additionally, the development of imaging techniques, such as MRI and transvaginal ultrasonography (TVUS), has allowed clinicians to make a non-invasive diagnosis of adenomyosis in women undergoing conservative treatments, identifying different disease phenotypes. After some attempts at histological classification, adenomyosis is classified into four subtypes according to MRI lesion localization in the inner or outer myometrium intrinsic, extrinsic, intramural, and indeterminate.
Moreover, a growing number of advancements in medical research to innovate various menopause treatments and products are projected to fuel the market's growth rate. In recent years, several key market participants have conducted research and developmental activities to bring various menopause products and treatments to the market to address the symptoms of menopause. For instance, several non-hormonal drugs have been developed by market participants in recent years that can effectively impact hot flashes and other menopause symptoms.
Owing to the growing number of adenomyosis products and services entering the market, the demand for these products is expected to drive the adenomyosis treatment market revenue.
The rising prevalence of vasomotor and menopausal signs, such as night efforts and hot flashes among women during menopausal change, is projected to drive market growth. In addition, problems such as mood swings, problems concentrating, and depression are linked to menopause. As per a study issued in the International Journal of Applied & Basic Medical Research, approximately 36.7% of women registered hot flashes among 87.7% of women conveying menopausal symptoms. The primary symptom noted was anxiety, which accounted for 80%, and sleep problems for 61.2%.
The increasing recognition of adenomyosis as a significant contributor to women's health issues is likely to drive advancements in treatment options and enhance patient outcomes.
U.S. National Library of Medicine
Adenomyosis Treatment Market Market Drivers
Rising Awareness and Education
The increasing awareness and education surrounding adenomyosis are pivotal in driving the Global Adenomyosis Treatment Market Industry. Healthcare campaigns aimed at educating women about the symptoms and treatment options available have led to more women seeking medical advice. This heightened awareness is crucial, as many women may previously have been unaware of their condition. As educational initiatives continue to expand, the market is likely to see a surge in demand for treatments. This trend aligns with the projected compound annual growth rate of 6.19% from 2025 to 2035, indicating a robust market trajectory.
Advancements in Treatment Modalities
Innovations in treatment modalities for adenomyosis are significantly influencing the Global Adenomyosis Treatment Market Industry. Recent developments in hormonal therapies, minimally invasive surgical techniques, and alternative treatments have provided patients with more options. For instance, the introduction of new medications that target specific hormonal pathways has shown promise in alleviating symptoms. These advancements not only improve patient outcomes but also encourage healthcare providers to adopt these new therapies, thereby expanding the market. As a result, the market is projected to grow, with an estimated value of 0.66 USD Billion by 2035.
Growing Investment in Women's Health
The growing investment in women's health initiatives is a significant factor propelling the Global Adenomyosis Treatment Market Industry. Governments and private organizations are increasingly recognizing the importance of addressing women's health issues, including adenomyosis. This investment is reflected in funding for research and development of new treatments, as well as initiatives aimed at improving access to care. As more resources are allocated to this sector, the market is expected to benefit from enhanced treatment options and increased patient access. This trend is likely to contribute to the overall growth of the market in the coming years.
Increasing Prevalence of Adenomyosis
The rising incidence of adenomyosis globally is a primary driver for the Global Adenomyosis Treatment Market Industry. As awareness of this condition grows, more women are seeking diagnosis and treatment options. Reports indicate that adenomyosis affects approximately 20-30% of women with uterine disorders, leading to a heightened demand for effective therapies. This trend is expected to contribute to the market's growth, with projections estimating the market value to reach 0.34 USD Billion in 2024. The increasing prevalence necessitates a broader range of treatment options, thereby stimulating market expansion.
Integration of Telemedicine in Treatment
The integration of telemedicine into the treatment landscape for adenomyosis is transforming the Global Adenomyosis Treatment Market Industry. Telehealth services enable patients to consult with specialists remotely, improving access to care, particularly for those in underserved areas. This shift towards digital health solutions has been accelerated by the need for convenient and timely medical consultations. As telemedicine continues to gain traction, it is likely to enhance patient engagement and adherence to treatment plans. This evolution in healthcare delivery could significantly impact market growth, as more patients seek out these accessible treatment options.
Market Segment Insights
Adenomyosis Treatment Type Insights
The adenomyosis treatment market segmentation, based on type, includes focal, adenomyoma, diffuse, and others. The adenomyoma segment dominated the market, accounting for 35% of market revenue (0.11 Billion). In developing economies, category growth is driven as adenomyoma is more commonly observed in women who have had multiple pregnancies or childbirths. However, focal is the fastest-growing category due to the growing elderly population and abnormal hormonal fluctuations.
Adenomyosis Treatment Diagnosis Insights
The adenomyosis treatment market segmentation, based on diagnosis, includes endometrial biopsy, ultrasound {transabdominal and transvaginal/endovaginal}, magnetic resonance imaging (MRI), and others. The magnetic resonance imaging (MRI) category generated the most income (70.4%) due to the increasing geriatric population and technological advancements. However, focal is the fastest-growing category due to rapid technological advancements in healthcare services and the increasing number of individuals admissions to emergency care for focal treatment.
Adenomyosis Treatment Treatment Insights
The adenomyosis treatment market segmentation, based on diagnosis, includes anti-inflammatory drugs {ibuprofen, Motrin IB, Advil, and others}, hormone medications {gonadotropin-releasing hormone (GnRH) agonists, aromatase inhibitors, and others}, hysterectomy {supracervial or subtotal hysterectomy, total hysterectomy, radical hysterectomy}, and others. The anti-inflammatory drugs category generated the most income due to the increasing research and development efforts on developing novel biologics. However, hormone medications are the fastest-growing category as they reduce adenomyotic lesion size and improve the patient's dysmenorrhea and quality of life.
Figure 1 Adenomyosis Treatment Market, by Diagnosis, 2022 & 2032 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Get more detailed insights about Adenomyosis Treatment Market Research Report -Forecast to 2034
Regional Insights
By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American adenomyosis treatment market will dominate, owing to an improved prevalence of post-menstrual syndrome, growing awareness regarding women's fitness, and increased healthcare expenditure will fuel the market growth in this region. Further, the US adenomyosis treatment market held the largest market share, and the Canada adenomyosis treatment market was the fastest growing market in the North American region.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2 ADENOMYOSIS TREATMENT MARKET SHARE BY REGION 2022 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe's adenomyosis treatment market accounts for the second-largest market share due to post-menstrual syndrome being prevalent and nutritional needs becoming more widely known in this region. Further, the German adenomyosis treatment market held the largest market share, and the UK adenomyosis treatment market was the fastest-growing market in the European region.
The Asia-Pacific adenomyosis treatment market is projected to grow at the fastest CAGR from 2023 to 2032. This is due to expanding awareness regarding adenomyosis and rising per capita disposable income. Moreover, China’s adenomyosis treatment market held the largest market share, and the Indian adenomyosis treatment market was the fastest-growing market in the Asia-Pacific region.
Key Players and Competitive Insights
Leading market participants are investing laboriously in research and development to boost their product lines, which will allow the adenomyosis treatment market to grow even better. Market participants are also undertaking various strategic exercises to develop their footprint, with substantial market developments including the latest product launches, mergers and acquisitions, contractual agreements, higher investments, and collaboration with other organizations. To develop and prevail in a more competitive and growing market climate, the adenomyosis treatment industry must deliver cost-effective items.
Manufacturing locally to decline operating costs is one of the key business tactics manufacturers operate in the adenomyosis treatment industry to help clients and increase the market sector. Major players in the adenomyosis treatment market, including Mayne Pharma Group Limited, Accord Healthcare, Tolmar Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, TerSera Therapeutics LLC, and others, are attempting to expand market need by investing in research and development processes.
Debiopharm is a family-owned biopharmaceutical company founded in 1979 and headquartered in Lausanne, Switzerland. The firm develops biologics and small-molecule drug candidates. Debiopharm drug development covers the formulation, manufacturing, pre-clinical, and clinical stages. Debiopharm products are used for tumors, such as testicular, ovarian, bladder, and lung carcinomas. The company develops biologics and small-molecule drug candidates. Debiopharm drug development covers the formulation, manufacturing, pre-clinical, and clinical stages. Debiopharm products are used for tumors, such as testicular, ovarian, bladder, and lung carcinomas.
Bayer AG is engaged in discovering, developing, manufacturing, and commercializing developments for human health and agriculture. It delivers medicines for women's health, cardiovascular diseases, cancer, hematology, ophthalmology, and other indications. It even aims to develop new molecules and technologies for treatment and modern agriculture. The company's product portfolio includes prescription, specialty pharmaceuticals, diagnostic imaging equipment, non-prescription (over-the-counter or OTC) products, seeds, crop protection, and non-agricultural pest control solutions. Bayer markets its healthcare and crop protection products through wholesalers, pharmacies, hospitals, and retailers.
In August 2020, Bayer acquired the UK-based biotech KaNDy Therapeutics Ltd. to develop its drug development pipeline in women's healthcare. KaNDy Therapeutics Ltd. achieved the NT-814 clinical trials to treat menopausal signs such as hot flashes and night sweats.
Key Companies in the Adenomyosis Treatment Market market include
Industry Developments
November 2021 Theramex obtained the Femarelle product license to treat menopause symptoms. These products will be available in different markets from the middle of 2022. This drug is used to balance the estrogen levels in women from perimenopause through menopause to post-menopause, relieving the symptoms and conditions.
October 2021 Bayer AG initiated the phase III clinical program OASIS. Under the program, elinzanetant, a dual neurokinin-1, 3 receptor antagonist, will be evaluated on the efficacy and safety standards for treating menopausal symptoms such as vasomotor symptoms.
September 2019 Professor Caroline Gargett and collaborators at the University of Queensland and Monash IVF were awarded a three-year USD 2.07 Million grant to determine the cause of adenomyosis and the physiological processes associated with the disease.
Future Outlook
Adenomyosis Treatment Market Future Outlook
The Global Adenomyosis Treatment Market is projected to grow at a 6.20% CAGR from 2025 to 2035, driven by increasing awareness, advancements in treatment options, and rising healthcare expenditure.
New opportunities lie in:
- Develop innovative non-invasive treatment modalities to enhance patient comfort and compliance.
- Expand telehealth services to improve access to specialized care for adenomyosis patients.
- Invest in targeted marketing strategies to raise awareness among healthcare professionals and patients.
By 2035, the Adenomyosis Treatment Market is expected to achieve substantial growth, reflecting evolving treatment paradigms and enhanced patient outcomes.
Market Segmentation
Adenomyosis Treatment Outlook
Anti-Inflammatory Drugs
- Ibuprofen
- Motrin IB
- Advil
- Others
Adenomyosis Treatment Type Outlook
- Focal
- Adenomyoma
- Diffuse
- Others
Adenomyosis Treatment Regional Outlook
North America
- US
- Canada
Adenomyosis Treatment Diagnosis Outlook
Ultrasound
- Transabdominal
- Transvaginal/Endovaginal
Report Scope
Adenomyosis Treatment Report Scope
| Attribute/Metric | Details |
| Market Size 2024 | 0.34 (USD Billion) |
| Market Size 2025 | 0.36 (USD Billion) |
| Market Size 2035 | 0.66 (USD Billion) |
| Compound Annual Growth Rate (CAGR) | 6.20% (2025 - 2035) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2020 - 2024 |
| Report Coverage | Market Competitive Landscape, Revenue Forecast, Growth Factors, and Trends |
| Segments Covered | Type, Treatment, Diagnosis, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Mayne Pharma Group Limited, Accord Healthcare, Tolmar Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, TerSera Therapeutics LLC, Ferring B.V., Lannett, Par Pharmaceutical, Hikma Pharmaceuticals PLC, Context Therapeutics Inc., Viatris Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., AstraZeneca, Pfizer Inc., Zydus Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd, AbbVie Inc., Abbott, GlaxoSmithKline plc. |
| Key Market Opportunities | High prevalence of adenomyosis disorders across the globe |
| Key Market Dynamics | Advancement in the diagnosis of adenomyosis |
Market Highlights
Author
Latest Comments
John Doe
john@example.com
This is a great article! Really helped me understand the topic better.
Posted on July 23, 2025, 10:15
AM
Jane Smith
jane@domain.com
Thanks for sharing this. I’ve bookmarked it for later reference.
Posted on July 22, 2025, 7:45
PM
FAQs
What is the projected growth of the Adenomyosis Treatment market?
The Adenomyosis Treatment market is the expected increase in total market value of 0.66 USD billion over a defined forecast period 2025–2035. It is driven by factors such as demand trends, technological advances, regulatory changes, and geographic expansion.
What is the size of the Adenomyosis Treatment market?
Adenomyosis Treatment market size was valued at approximately 0.34 billion USD in 2024. This figure will reach 0.66 billion USD covering all regions (America, Europe, Asia, MEA and ROW), focusing its segments / services / distribution channels till 2035.
What is the CAGR of the Adenomyosis Treatment market?
Adenomyosis Treatment market is expected to grow at a CAGR of 6.2% between 2025 and 2035.
How much will the Adenomyosis Treatment market be worth by 2035?
Adenomyosis Treatment market is expected to be worth of 0.66 billion USD, reflecting growth driven by usage, technology and global demands by the end of 2035.
How will the Adenomyosis Treatment market perform over the next 10 years?
Over the next 10 years the Adenomyosis Treatment market is expected to shift from usd billion 0.34 to 0.66 billion USD, led by adoption of advanced tech, demographic trends, regulatory approvals, with potential headwinds from 2025 to 2035.
Which region held the most extensive market share in the adenomyosis treatment market?
North America had the most extensive share of the market
Who are the key players in the adenomyosis treatment market?
The key players in the market are Hikma Pharmaceuticals PLC, Context Therapeutics Inc., Viatris Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., AstraZeneca, Pfizer Inc., Zydus Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd, AbbVie Inc., Abbott, GlaxoSmithKline plc.
-
|- Table of Content 1. Report Prologue
-
Introduction
- Definition
-
Scope of the Study
- Research Objective
- Assumptions
- Limitations
- Market Structure
- Market Segmentation
-
Research Methodology
- Research Process
- Primary Research
- Secondary Research
- Market Size Estimation
- Forecast Model
-
Market Dynamics
- Drivers
- Restraints
- Opportunities
- Mega Trends
- Macroeconomic Indicators
-
Market Factor analysis
- Value Chain Analysis
- Porters Five Forces
- Demand & Supply: Gap Analysis
- Pricing Analysis
- Investment Opportunity Analysis
- Merger and Acquisition Landscape
-
Upcoming trends
- Market trends
- Technological trends
- Insurance & Regulations
- Others
-
Global Adenomyosis Treatment Market by Type
- Focal
- Adenomyoma
- Diffuse
- Others
-
Global Adenomyosis Treatment Market by Diagnosis
- Endometrial biopsy
-
Ultrasound
- Transabdominal
- Transvaginal/endovaginal
- Magnetic resonance imaging (MRI)
- Others
-
Global Adenomyosis Treatment Market by Treatment
-
Anti-inflammatory drugs
- Ibuprofen
- Motrin IB
- Advil
- Others
-
Hormone medications
- Gonadotropin-releasing hormone (GnRH) agonists
- Aromatase inhibitors
- Others
-
Hysterectomy
- Supracervial or subtotal hysterectomy
- Total hysterectomy
- Radical hysterectomy
- Others
-
Anti-inflammatory drugs
-
Global Adenomyosis Treatment Market by Region
- Introduction
-
America
- North America
- South America
-
Europe
- Western Europe
- Eastern Europe
-
Asia
- China
- India
- Japan
- South Korea
- Rest of Asia
- Pacific
-
Middle East and Africa
- UAE
- Saudi Arabia
- Egypt
- Rest of Middle East and Africa
-
Competitive Landscape
-
Company profile
-
12 Conclusion
-
Key Findings
- From CEO’s viewpoint
- Unmet needs of the market
- Key companies to watch
- Prediction of Adenomyosis Treatment Market
-
Key Findings
-
13 Appendix
Adenomyosis Treatment Market Segmentation
Adenomyosis Treatment Type Outlook (USD Billion, 2018-2032)
- Focal
- Adenomyoma
- Diffuse
- Others
Adenomyosis Treatment Diagnosis Outlook (USD Billion, 2018-2032)
- Endometrial Biopsy
- Ultrasound
- Transabdominal
- Transvaginal/Endovaginal
- Magnetic Resonance Imaging (MRI)
- Others
Adenomyosis Treatment Outlook (USD Billion, 2018-2032)
- Anti-Inflammatory Drugs
- Ibuprofen
- Motrin IB
- Advil
- Others
- Hormone Medications
- Gonadotropin-Releasing Hormone (GnRH) Agonists
- Aromatase Inhibitors
- Others
- Hysterectomy
- Supracervial Or Subtotal Hysterectomy
- Total Hysterectomy
- Radical Hysterectomy
- Others
Adenomyosis Treatment Regional Outlook (USD Billion, 2018-2032)
North America Outlook (USD Billion, 2018-2032)
- North America Adenomyosis Treatment by Type
- Focal
- Adenomyoma
- Diffuse
- Others
- North America Adenomyosis Treatment by Diagnosis
- Endometrial Biopsy
Ultrasound
- Transabdominal
- Transvaginal/Endovaginal
- Magnetic Resonance Imaging (MRI)
- Others
- North America Adenomyosis Treatment by Treatment
Anti-Inflammatory Drugs
- Ibuprofen
- Motrin IB
- Advil
- Others
Hormone Medications
- Gonadotropin-Releasing Hormone (GnRH) Agonists
- Aromatase Inhibitors
- Others
Hysterectomy
- Supracervial Or Subtotal Hysterectomy
- Total Hysterectomy
- Radical Hysterectomy
- Others
US Outlook (USD Billion, 2018-2032)
- US Adenomyosis Treatment by Type
- Focal
- Adenomyoma
- Diffuse
- Others
- US Adenomyosis Treatment by Diagnosis
- Endometrial Biopsy
Ultrasound
- Transabdominal
- Transvaginal/Endovaginal
- Magnetic Resonance Imaging (MRI)
- Others
- US Adenomyosis Treatment by Treatment
Anti-Inflammatory Drugs
- Ibuprofen
- Motrin IB
- Advil
- Others
Hormone Medications
- Gonadotropin-Releasing Hormone (GnRH) Agonists
- Aromatase Inhibitors
- Others
Hysterectomy
- Supracervial Or Subtotal Hysterectomy
- Total Hysterectomy
- Radical Hysterectomy
- Others
CANADA Outlook (USD Billion, 2018-2032)
- CANADA Adenomyosis Treatment by Type
- Focal
- Adenomyoma
- Diffuse
- Others
- CANADA Adenomyosis Treatment by Diagnosis
- Endometrial Biopsy
Ultrasound
- Transabdominal
- Transvaginal/Endovaginal
- Magnetic Resonance Imaging (MRI)
- Others
- CANADA Adenomyosis Treatment by Treatment
Anti-Inflammatory Drugs
- Ibuprofen
- Motrin IB
- Advil
- Others
Hormone Medications
- Gonadotropin-Releasing Hormone (GnRH) Agonists
- Aromatase Inhibitors
- Others
Hysterectomy
- Supracervial Or Subtotal Hysterectomy
- Total Hysterectomy
- Radical Hysterectomy
- Others
- North America Adenomyosis Treatment by Type
Europe Outlook (USD Billion, 2018-2032)
- Europe Adenomyosis Treatment by Type
- Focal
- Adenomyoma
- Diffuse
- Others
- Europe Adenomyosis Treatment by Diagnosis
- Endometrial Biopsy
Ultrasound
- Transabdominal
- Transvaginal/Endovaginal
- Magnetic Resonance Imaging (MRI)
- Others
- Europe Adenomyosis Treatment by Treatment
Anti-Inflammatory Drugs
- Ibuprofen
- Motrin IB
- Advil
- Others
Hormone Medications
- Gonadotropin-Releasing Hormone (GnRH) Agonists
- Aromatase Inhibitors
- Others
Hysterectomy
- Supracervial Or Subtotal Hysterectomy
- Total Hysterectomy
- Radical Hysterectomy
- Others
Germany Outlook (USD Billion, 2018-2032)
- Germany Adenomyosis Treatment by Type
- Focal
- Adenomyoma
- Diffuse
- Others
- Germany Adenomyosis Treatment by Diagnosis
- Endometrial Biopsy
Ultrasound
- Transabdominal
- Transvaginal/Endovaginal
- Magnetic Resonance Imaging (MRI)
- Others
- Germany Adenomyosis Treatment by Treatment
Anti-Inflammatory Drugs
- Ibuprofen
- Motrin IB
- Advil
- Others
Hormone Medications
- Gonadotropin-Releasing Hormone (GnRH) Agonists
- Aromatase Inhibitors
- Others
Hysterectomy
- Supracervial Or Subtotal Hysterectomy
- Total Hysterectomy
- Radical Hysterectomy
- Others
France Outlook (USD Billion, 2018-2032)
- France Adenomyosis Treatment by Type
- Focal
- Adenomyoma
- Diffuse
- Others
- France Adenomyosis Treatment by Treatment
Anti-Inflammatory Drugs
- Ibuprofen
- Motrin IB
- Advil
- Others
Hormone Medications
- Gonadotropin-Releasing Hormone (GnRH) Agonists
- Aromatase Inhibitors
- Others
Hysterectomy
- Supracervial Or Subtotal Hysterectomy
- Total Hysterectomy
- Radical Hysterectomy
- Others
- France Adenomyosis Treatment by Diagnosis
- Endometrial Biopsy
Ultrasound
- Transabdominal
- Transvaginal/Endovaginal
- Magnetic Resonance Imaging (MRI)
- Others
UK Outlook (USD Billion, 2018-2032)
- UK Adenomyosis Treatment by Type
- Focal
- Adenomyoma
- Diffuse
- Others
- UK Adenomyosis Treatment by Diagnosis
- Endometrial Biopsy
Ultrasound
- Transabdominal
- Transvaginal/Endovaginal
- Magnetic Resonance Imaging (MRI)
- Others
- UK Adenomyosis Treatment by Treatment
Anti-Inflammatory Drugs
- Ibuprofen
- Motrin IB
- Advil
- Others
Hormone Medications
- Gonadotropin-Releasing Hormone (GnRH) Agonists
- Aromatase Inhibitors
- Others
Hysterectomy
- Supracervial Or Subtotal Hysterectomy
- Total Hysterectomy
- Radical Hysterectomy
- Others
ITALY Outlook (USD Billion, 2018-2032)
- ITALY Adenomyosis Treatment by Type
- Focal
- Adenomyoma
- Diffuse
- Others
- ITALY Adenomyosis Treatment by Diagnosis
- Endometrial Biopsy
Ultrasound
- Transabdominal
- Transvaginal/Endovaginal
- Magnetic Resonance Imaging (MRI)
- Others
- ITALY Adenomyosis Treatment by Treatment
Anti-Inflammatory Drugs
- Ibuprofen
- Motrin IB
- Advil
- Others
Hormone Medications
- Gonadotropin-Releasing Hormone (GnRH) Agonists
- Aromatase Inhibitors
- Others
Hysterectomy
- Supracervial Or Subtotal Hysterectomy
- Total Hysterectomy
- Radical Hysterectomy
- Others
SPAIN Outlook (USD Billion, 2018-2032)
- Spain Adenomyosis Treatment by Type
- Focal
- Adenomyoma
- Diffuse
- Others
- Spain Adenomyosis Treatment by Diagnosis
- Endometrial Biopsy
Ultrasound
- Transabdominal
- Transvaginal/Endovaginal
- Magnetic Resonance Imaging (MRI)
- Others
- Spain Adenomyosis Treatment by Treatment
Anti-Inflammatory Drugs
- Ibuprofen
- Motrin IB
- Advil
- Others
Hormone Medications
- Gonadotropin-Releasing Hormone (GnRH) Agonists
- Aromatase Inhibitors
- Others
Hysterectomy
- Supracervial Or Subtotal Hysterectomy
- Total Hysterectomy
- Radical Hysterectomy
- Others
Rest Of Europe Outlook (USD Billion, 2018-2032)
- Rest Of Europe Adenomyosis Treatment by Type
- Focal
- Adenomyoma
- Diffuse
- Others
- REST OF EUROPE Adenomyosis Treatment by Diagnosis
- Endometrial Biopsy
Ultrasound
- Transabdominal
- Transvaginal/Endovaginal
- Magnetic Resonance Imaging (MRI)
- Others
- Rest Of Europe Adenomyosis Treatment by Treatment
Anti-Inflammatory Drugs
- Ibuprofen
- Motrin IB
- Advil
- Others
Hormone Medications
- Gonadotropin-Releasing Hormone (GnRH) Agonists
- Aromatase Inhibitors
- Others
Hysterectomy
- Supracervial Or Subtotal Hysterectomy
- Total Hysterectomy
- Radical Hysterectomy
- Others
- Europe Adenomyosis Treatment by Type
Asia-Pacific Outlook (USD Billion, 2018-2032)
- Asia-Pacific Adenomyosis Treatment by Type
- Focal
- Adenomyoma
- Diffuse
- Others
- Asia-Pacific Adenomyosis Treatment by Diagnosis
- Endometrial Biopsy
Ultrasound
- Transabdominal
- Transvaginal/Endovaginal
- Magnetic Resonance Imaging (MRI)
- Others
- Asia-Pacific Adenomyosis Treatment by Treatment
Anti-Inflammatory Drugs
- Ibuprofen
- Motrin IB
- Advil
- Others
Hormone Medications
- Gonadotropin-Releasing Hormone (GnRH) Agonists
- Aromatase Inhibitors
- Others
Hysterectomy
- Supracervial Or Subtotal Hysterectomy
- Total Hysterectomy
- Radical Hysterectomy
- Others
China Outlook (USD Billion, 2018-2032)
- China Adenomyosis Treatment by Type
- Focal
- Adenomyoma
- Diffuse
- Others
- China Adenomyosis Treatment by Diagnosis
- Endometrial Biopsy
Ultrasound
- Transabdominal
- Transvaginal/Endovaginal
- Magnetic Resonance Imaging (MRI)
- Others
- China Adenomyosis Treatment by Treatment
Anti-Inflammatory Drugs
- Ibuprofen
- Motrin IB
- Advil
- Others
Hormone Medications
- Gonadotropin-Releasing Hormone (GnRH) Agonists
- Aromatase Inhibitors
- Others
Hysterectomy
- Supracervial Or Subtotal Hysterectomy
- Total Hysterectomy
- Radical Hysterectomy
- Others
Japan Outlook (USD Billion, 2018-2032)
- Japan Adenomyosis Treatment by Type
- Focal
- Adenomyoma
- Diffuse
- Others
- Japan Adenomyosis Treatment by Treatment
Anti-Inflammatory Drugs
- Ibuprofen
- Motrin IB
- Advil
- Others
Hormone Medications
- Gonadotropin-Releasing Hormone (GnRH) Agonists
- Aromatase Inhibitors
- Others
Hysterectomy
- Supracervial Or Subtotal Hysterectomy
- Total Hysterectomy
- Radical Hysterectomy
- Others
- Japan Adenomyosis Treatment by Diagnosis
- Endometrial Biopsy
Ultrasound
- Transabdominal
- Transvaginal/Endovaginal
- Magnetic Resonance Imaging (MRI)
- Others
India Outlook (USD Billion, 2018-2032)
- India Adenomyosis Treatment by Type
- Focal
- Adenomyoma
- Diffuse
- Others
- India Adenomyosis Treatment by Diagnosis
- Endometrial Biopsy
Ultrasound
- Transabdominal
- Transvaginal/Endovaginal
- Magnetic Resonance Imaging (MRI)
- Others
- India Adenomyosis Treatment by Treatment
Anti-Inflammatory Drugs
- Ibuprofen
- Motrin IB
- Advil
- Others
Hormone Medications
- Gonadotropin-Releasing Hormone (GnRH) Agonists
- Aromatase Inhibitors
- Others
Hysterectomy
- Supracervial Or Subtotal Hysterectomy
- Total Hysterectomy
- Radical Hysterectomy
- Others
Australia Outlook (USD Billion, 2018-2032)
- Australia Adenomyosis Treatment by Type
- Focal
- Adenomyoma
- Diffuse
- Others
- Australia Adenomyosis Treatment by Treatment
Anti-Inflammatory Drugs
- Ibuprofen
- Motrin IB
- Advil
- Others
Hormone Medications
- Gonadotropin-Releasing Hormone (GnRH) Agonists
- Aromatase Inhibitors
- Others
Hysterectomy
- Supracervial Or Subtotal Hysterectomy
- Total Hysterectomy
- Radical Hysterectomy
- Others
- Australia Adenomyosis Treatment by Diagnosis
- Endometrial Biopsy
Ultrasound
- Transabdominal
- Transvaginal/Endovaginal
- Magnetic Resonance Imaging (MRI)
- Others
Rest of Asia-Pacific Outlook (USD Billion, 2018-2032)
- Rest of Asia-Pacific Adenomyosis Treatment by Type
- Focal
- Adenomyoma
- Diffuse
- Others
- Rest of Asia-Pacific Adenomyosis Treatment by Treatment
Anti-Inflammatory Drugs
- Ibuprofen
- Motrin IB
- Advil
- Others
Hormone Medications
- Gonadotropin-Releasing Hormone (GnRH) Agonists
- Aromatase Inhibitors
- Others
Hysterectomy
- Supracervial Or Subtotal Hysterectomy
- Total Hysterectomy
- Radical Hysterectomy
- Others
- Rest of Asia-Pacific Adenomyosis Treatment by Diagnosis
- Endometrial Biopsy
Ultrasound
- Transabdominal
- Transvaginal/Endovaginal
- Magnetic Resonance Imaging (MRI)
- Others
- Asia-Pacific Adenomyosis Treatment by Type
Rest of the World Outlook (USD Billion, 2018-2032)
- Rest of the World Adenomyosis Treatment by Type
- Focal
- Adenomyoma
- Diffuse
- Others
- Rest of the World Adenomyosis Treatment by Treatment
Anti-Inflammatory Drugs
- Ibuprofen
- Motrin IB
- Advil
- Others
Hormone Medications
- Gonadotropin-Releasing Hormone (GnRH) Agonists
- Aromatase Inhibitors
- Others
Hysterectomy
- Supracervial Or Subtotal Hysterectomy
- Total Hysterectomy
- Radical Hysterectomy
- Others
- Rest of the World Adenomyosis Treatment by Diagnosis
- Endometrial Biopsy
Ultrasound
- Transabdominal
- Transvaginal/Endovaginal
- Magnetic Resonance Imaging (MRI)
- Others
Middle East Outlook (USD Billion, 2018-2032)
- Middle East Adenomyosis Treatment by Type
- Focal
- Adenomyoma
- Diffuse
- Others
- Middle East Adenomyosis Treatment by Diagnosis
- Endometrial Biopsy
Ultrasound
- Transabdominal
- Transvaginal/Endovaginal
- Magnetic Resonance Imaging (MRI)
- Others
- Middle East Adenomyosis Treatment by Treatment
Anti-Inflammatory Drugs
- Ibuprofen
- Motrin IB
- Advil
- Others
Hormone Medications
- Gonadotropin-Releasing Hormone (GnRH) Agonists
- Aromatase Inhibitors
- Others
Hysterectomy
- Supracervial Or Subtotal Hysterectomy
- Total Hysterectomy
- Radical Hysterectomy
- Others
Africa Outlook (USD Billion, 2018-2032)
- Africa Adenomyosis Treatment by Type
- Focal
- Adenomyoma
- Diffuse
- Others
- Africa Adenomyosis Treatment by Diagnosis
- Endometrial Biopsy
Ultrasound
- Transabdominal
- Transvaginal/Endovaginal
- Magnetic Resonance Imaging (MRI)
- Others
- Africa Adenomyosis Treatment by Treatment
Anti-Inflammatory Drugs
- Ibuprofen
- Motrin IB
- Advil
- Others
Hormone Medications
- Gonadotropin-Releasing Hormone (GnRH) Agonists
- Aromatase Inhibitors
- Others
Hysterectomy
- Supracervial Or Subtotal Hysterectomy
- Total Hysterectomy
- Radical Hysterectomy
- Others
Latin America Outlook (USD Billion, 2018-2032)
- Latin America Adenomyosis Treatment by Type
- Focal
- Adenomyoma
- Diffuse
- Others
- Latin America Adenomyosis Treatment by Diagnosis
- Endometrial Biopsy
Ultrasound
- Transabdominal
- Transvaginal/Endovaginal
- Magnetic Resonance Imaging (MRI)
- Others
- Latin America Adenomyosis Treatment by Treatment
Anti-Inflammatory Drugs
- Ibuprofen
- Motrin IB
- Advil
- Others
Hormone Medications
- Gonadotropin-Releasing Hormone (GnRH) Agonists
- Aromatase Inhibitors
- Others
Hysterectomy
- Supracervial Or Subtotal Hysterectomy
- Total Hysterectomy
- Radical Hysterectomy
- Others
- Rest of the World Adenomyosis Treatment by Type
Free Sample Request
Kindly complete the form below to receive a free sample of this Report
Customer Strories
“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”
Leave a Comment